Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial (vol 41, pg 3329, 2023)

被引：0
|
作者：
Iwase, Takuji
Saji, Shigehira
Iijima, Kotaro
Higaki, Kenji
Ohtani, Shoichiro
Sato, Yasuyuki
Hozumi, Yasuo
Hasegawa, Yoshie
Yanagita, Yasuhiro
Takei, Hiroyuki
Tanaka, Maki
Masuoka, Hideji
Tanabe, Masahiko
Egawa, Chiyomi
Komoike, Yoshifumi
Nakamura, Toshitaka
Ohtsu, Hiroshi
Mukai, Hirofumi
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 23期
关键词：
D O I：
10.1200/JCO.23.01230
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：3962 / 3962
页数：1
相关论文
共 50 条
  • [1] Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial
    Iwase, Takuji
    Saji, Shigehira
    Iijima, Kotaro
    Higaki, Kenji
    Ohtani, Shoichiro
    Sato, Yasuyuki
    Hozumi, Yasuo
    Hasegawa, Yoshie
    Yanagita, Yasuhiro
    Takei, Hiroyuki
    Tanaka, Maki
    Masuoka, Hideji
    Tanabe, Masahiko
    Egawa, Chiyomi
    Komoike, Yoshifumi
    Nakamura, Toshitaka
    Ohtsu, Hiroshi
    Mukai, Hirofumi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3329 - +
  • [2] FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer
    Bergh, Jonas
    Jonsson, Per-Ebbe
    Lidbrink, Elisabet Kerstin
    Trudeau, Maureen
    Eiermann, Wolfgang
    Brattstrom, Daniel
    Lindemann, Justin P. O.
    Wiklund, Fredrik
    Henriksson, Roger
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) : 1919 - 1925
  • [3] Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial
    Heudel, Pierre
    Frenel, Jean-Sebastien
    Dalban, Cecile
    Bazan, Fernando
    Joly, Florence
    Arnaud, Antoine
    Abdeddaim, Cyril
    Chevalier-Place, Annick
    Augereau, Paule
    Pautier, Patricia
    Chakiba, Camille
    You, Benoit
    Lancry-Lecomte, Laurence
    Garin, Gwenaelle
    Marcel, Virginie
    Diaz, Jean Jacques
    Treilleux, Isabelle
    Perol, David
    Fabbro, Michel
    Ray-Coquard, Isabelle
    JAMA ONCOLOGY, 2022, 8 (07) : 1001 - 1009
  • [4] Phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor-positive/HER2-negative resected isolated locoregional recurrence of breast cancer - The POLAR Trial
    Munzone, Elisabetta
    Aebi, Stefan
    Janez, Noelia Martinez
    Guth, Uwe
    Bellet, Meritxell
    Pistilli, Barbara
    Balic, Marija
    Roschitzki-Voser, Heidi
    Regan, Meredith M.
    CANCER RESEARCH, 2021, 81 (04)
  • [5] First Results from FACT - An Open-Label, Randomized Phase III Study Investigating Loading Dose of Fulvestrant Combined with Anastrozole Versus Anastrozole at First Relapse in Hormone Receptor Positive Breast Cancer
    Bergh, J.
    Jonsson, P. E.
    Lidbrink, E.
    Trudeau, M.
    Eiermann, W.
    Brattstrom, D.
    Lindemann, J.
    Wiklund, F.
    Henriksson, R.
    CANCER RESEARCH, 2009, 69 (24) : 490S - 491S
  • [6] A prospective, randomized, multicenter, comparative and open-label study on hepatotoxicity of anastrozole compared with tamoxifen in adjuvant therapy in postmenopausal women with hormone receptor plus early breast cancer
    Lin, Y.
    Liu, J. L.
    Zhang, X. H.
    Li, L.
    Hu, R.
    Liu, J.
    Deng, Y. C.
    Chen, D. D.
    Zhao, Y. B.
    Wang, S. M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S466 - S466
  • [7] A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial
    Ottenbourgs, Tine
    van Gorp, Toon
    Kridelka, Frederic
    Baert, Thais
    Denys, Hannelore
    Selle, Frederic
    Baas, Inge
    Van Rompuy, Anne-Sophie
    Lambrechts, Diether
    Van Nieuwenhuysen, Els
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (04) : 627 - 630
  • [8] Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial
    Smith, Ian
    Yardley, Denise
    Burris, Howard
    De Boer, Richard
    Amadori, Dino
    McIntyre, Kristi
    Ejlertsen, Bent
    Gnant, Michael
    Jonat, Walter
    Pritchard, Kathleen I.
    Dowsett, Mitch
    Hart, Lowell
    Poggio, Susan
    Comarella, Lisa
    Salomon, Herve
    Wamil, Barbara
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (10) : 1041 - +
  • [9] A randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer
    Connolly, Roisin M.
    Zhao, Fengmin
    Miller, Kathy D.
    Tevaarwerk, Amye J.
    Wagner, Lynne I.
    Lee, Min-Jung
    Murray, Judy
    Gray, Robert
    Piekarz, Richard L.
    Zujewski, Jo Anne A.
    Sparano, Joseph A.
    CANCER RESEARCH, 2015, 75
  • [10] Early versus conventional adjuvant chemotherapy in stage III colon cancer: A multicenter, randomized, open-label, phase 3 trial
    Park, Soo Yeun
    Kim, So Hyun
    Lee, Kyung Ha
    Song, Seung Ho
    Kim, Hye Jin
    Kim, Jong Gwang
    Kang, Byung Woog
    Baek, Seong Kyu
    Jeong, Woon Kyung
    Bae, Sung Uk
    Lee, In Kyu
    Lee, Yoon Suk
    Son, Gyung Mo
    Bae, Ki Beom
    Kim, Ji Yeon
    Park, Jun Seok
    Choi, Gyu-Seog
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345